Clinical Trials on MDD in Belgium

Total 34 results

Erasme University Hospital

Completed

Evaluation of the Effectiveness of the Supraclavicular Block Associated With a Pecs Blocks I to Ensure Analgesia When Placing a Pacemaker

Pain | Pacemaker Ddd

Belgium
Groupe Francophone des Myelodysplasies
Novartis

Unknown

A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS (GFM-EXVD-AZA)

MDS

France, Belgium
Jessa Hospital

Completed

Clinical Benefit of Rigourous AV Delay Optimization in Patients With a Dual Chamber Pacemaker (CBRAVO)

Quality of Life | Pacemaker Ddd Permanent | Atrial Dysfunction

Belgium
Universitaire Ziekenhuizen KU Leuven
Medtronics, Inc.

Completed

Evaluation of VDD Leadless Pacing System During Exercise

Bradycardia | Pacemaker DDD

Belgium
Allergan Medical

Completed

The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face

Age-related Volume Deficit in the Mid-face

Belgium, Netherlands, Germany, United Kingdom
Celyad Oncology SA
IQVIA Biotech

Completed

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 (DEPLETHINK)

AML | MDS

United States, Belgium
Amgen

Completed

Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS)

Belgium
Advanced Aesthetic Technologies, Inc

Recruiting

Algeness DF 3.5% Compared to Voluma in Volume Deficit in Mid-face

Age-Related Volume Deficit in the Mid-Face

Belgium, France, Germany, Israel, Malaysia, Spain, United Arab Emirates
Santhera Pharmaceuticals

Completed

Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy (DELPHI)

Duchenne Muscular Dystrophy (DMD)

Belgium
Benvenue Medical, Inc.

Unknown

Luna Interbody System for Fusion Trial (LIFT)

Lower Back Pain | Degenerative Disc Disease (DDD)

Germany, Belgium
Onze Lieve Vrouw Hospital

Unknown

Home-Based tDCS in Children With ADHD: A Randomized, Sham-Controlled tDCS and fNIRS Study

Attention Deficit Hyperactivity Disorder (ADHD) | Attention Deficit Disorder (ADD)

Belgium
Cell Medica Ltd
University College, London; Cell Therapy Catapult

Completed

A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

United Kingdom, Germany, Belgium
Stichting Hemato-Oncologie voor Volwassenen Nederland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients (HO155)

AML/MDS

Netherlands, Belgium, Germany, Switzerland
European Society for Blood and Marrow Transplantation
Novartis

Completed

Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML

MDS | CMML

Germany, Belgium, Czechia
Novartis Pharmaceuticals

Completed

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants (STIMULUS-MDS3)

Myelodysplastic Syndrome (MDS)

France, Spain, Belgium, Italy, Greece, Hungary, Germany
University of Siena
European Association of Cardiovascular Imaging

Active, not recruiting

Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE) (FUTURE-HIT)

Heart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection Fraction

Spain, Greece, Turkey, Portugal, Australia, Belgium, Italy, Mexico, Netherlands, North Macedonia, Romania, Tunisia
Amgen

Completed

Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

MDS

Germany, Italy, Belgium, Czechia, Switzerland, France, Austria, Greece, Spain
Celgene

Recruiting

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Beta-thalassemia | Myelodysplastic Syndromes (MDS) | Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

United States, Japan, United Kingdom, Turkey, Greece, France, Australia, Belgium, Bulgaria, Canada, Germany, Israel, Italy, Malaysia, Spain, Sweden, Taiwan, Thailand, Tunisia, Lebanon, China, Netherlands
Amoneta Diagnostics SAS
Assistance Publique - Hôpitaux de Paris; University Hospital, Geneva; University... and other collaborators

Unknown

ADDIA Proof-of-Performance Clinical Study (ADDIA)

Frontotemporal Lobar Degeneration | Progressive Supranuclear Palsy (PSP) | Dementia With Lewy Bodies (DLB) | Corticobasal Degeneration (CBD) | Alzheimer Disease (AD) | Parkinson Disease Dementia (PDD)

Belgium, France, Italy, Switzerland, Turkey
Dyne Therapeutics

Recruiting

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping (DELIVER)

Duchenne Muscular Dystrophy (DMD)

United States, Belgium, Canada, United Kingdom, Australia, Spain, Italy
AbbVie
Genentech, Inc.

Active, not recruiting

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona)

Myelodysplastic Syndrome (MDS)

United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Hungary
Shire

Terminated

Natural History Study of Children With Metachromatic Leukodystrophy

Metabolic Diseases | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Demyelinating Diseases | Genetic Diseases, Inborn | Metabolism, Inborn Errors | Lysosomal Storage Diseases | Lipid Metabolism Disorders | Sphingolipidoses | Hereditary Central Nervous System Demyelinating Diseases and other conditions

United States, Denmark, France, Argentina, Belgium, Brazil, Canada, Germany, Japan, Turkey
Santhera Pharmaceuticals

Terminated

A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids (SIDEROS)

Duchenne Muscular Dystrophy (DMD)

United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
Novartis Pharmaceuticals

Terminated

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Thrombocytopaenia

United States, Belgium, Australia, Canada, Hong Kong, Austria, Brazil, Czechia, Israel, Russian Federation, Spain, Sweden, Thailand, Denmark, France, Germany, Ireland, Italy, Korea, Republic of, Peru, Switzerland, Taiwan, Turkey, Hungary and more
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
Onconova Therapeutics, Inc.
The Leukemia and Lymphoma Society

Completed

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts (ONTIME)

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | MDS | RAEB

United States, Belgium, Germany, Spain, France, Italy
Forest Laboratories

Completed

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

Autistic Disorder | Autism | Autism Spectrum Disorders | Asperger Syndrome | Asperger's Disorder | Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)

United States, Belgium, Colombia, Estonia, France, Hungary, Iceland, Italy, Korea, Republic of, New Zealand, Poland, Serbia, South Africa, Spain, Ukraine
Forest Laboratories

Terminated

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Autistic Disorder | Autism | Asperger's Disorder | Autism Spectrum Disorder (ASD) | Asperger's | Pediatric Autism | Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

United States, Estonia, Hungary, Iceland, Italy, Korea, Republic of, Serbia, Ukraine, Canada, Colombia, Belgium, France, New Zealand, Poland, South Africa, Spain
Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy (EMBOLDEN)

Metachromatic Leukodystrophy (MLD)

United States, Canada, Belgium, Israel, Netherlands, United Kingdom, Germany, Spain, Japan, Brazil, Argentina, France, Greece, Italy
Forest Laboratories

Completed

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Autistic Disorder | Autism | Asperger's Disorder | Autism Spectrum Disorder (ASD) | Asperger's | Pediatric Autism | Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

United States, Belgium, Colombia, Estonia, Hungary, Iceland, Italy, Korea, Republic of, New Zealand, Poland, Serbia, South Africa, Spain, Ukraine, Australia, Canada, France, Singapore
Onconova Therapeutics, Inc.

Terminated

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

Myelodysplastic Syndrome | MDS | Refractory Anemia With Excess Blasts | RAEB

United States, Spain, Canada, France, Australia, Switzerland, Israel, Japan, Belgium, India, Ireland, United Kingdom, Croatia, Czechia, Poland, Estonia, Germany, Italy, Austria, Hungary, Russian Federation, Sweden
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Myeloproliferative Neoplasms (MPNs)

United States, Spain, Korea, Republic of, France, Taiwan, Australia, Belgium, Singapore, Israel, Canada, Germany, Finland
Constellation Pharmaceuticals
The Leukemia and Lymphoma Society

Active, not recruiting

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Neoplasms | Neoplasms by Histologic Type | Leukemia | Preleukemia | Primary Myelofibrosis | Myeloproliferative Disorders | Myelofibrosis | Precancerous Conditions | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic Syndrome (MDS) | Leukemia, Myelocytic, Acute | Bone Marrow Disease | Hematological Disease and other conditions

Canada, United States, United Kingdom, Germany, Italy, Belgium, France, Netherlands, Poland
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALIANT)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Spain, France, Germany, United Kingdom, Netherlands, Brazil, Israel, Japan, Australia, Austria, Italy, Switzerland, Korea, Republic of, Czechia, Belgium, Argentina, Canada, Poland

Clinical Trials on MDD in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations